Venrock Healthcare Capital Partners III, L.P.
CIK: 0001738048
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (31 total)
- Oct 30, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect8.8K shares at avg. $26.27$231K - Oct 30, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect200 shares at avg. $26.86$5K - Oct 29, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect1K shares at avg. $26.33$26K - Oct 28, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect4.4K shares at avg. $25.97$115K - Oct 28, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect10.6K shares at avg. $25.23$267K - Oct 27, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect8.7K shares at avg. $25.84$226K - Oct 27, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect31.1K shares at avg. $26.84$834K - Oct 26, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect8.3K shares at avg. $26.97$223K - Oct 26, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect1.9M shares at avg. $18.00$35.0M - Oct 26, 2026LYCA
Lycia Therapeutics, Inc.
Conversion(C)Indirect4.8M shares- - Oct 23, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect24.6K shares at avg. $25.68$631K - Oct 23, 2026LYCA
Lycia Therapeutics, Inc.
Purchase(P)Indirect28.4K shares at avg. $26.11$741K - Mar 26, 2026KALV
KalVista Pharmaceuticals, Inc.
Sale(S)Indirect15.4K shares at avg. $18.82$290K - Mar 26, 2026KALV
KalVista Pharmaceuticals, Inc.
Sale(S)Indirect3.2K shares at avg. $19.12$61K - Mar 26, 2026KALV
KalVista Pharmaceuticals, Inc.
Sale(S)Indirect21.4K shares at avg. $17.76$380K - Mar 25, 2026KALV
KalVista Pharmaceuticals, Inc.
Sale(S)Indirect174.5K shares at avg. $16.95$3.0M - Mar 25, 2026KALV
KalVista Pharmaceuticals, Inc.
Sale(S)Indirect160 shares at avg. $17.53$3K - Apr 9, 2025KALV
KalVista Pharmaceuticals, Inc.
Purchase(P)Indirect25K shares at avg. $9.42$236K - Feb 14, 2025ORKA
Oruka Therapeutics, Inc.
Purchase(P)Indirect88.8K shares at avg. $11.44$1.0M - Feb 13, 2025ORKA
Oruka Therapeutics, Inc.
Purchase(P)Indirect15K shares at avg. $11.63$174K - Feb 13, 2025KALV
KalVista Pharmaceuticals, Inc.
Purchase(P)Indirect61.7K shares at avg. $9.33$576K - Feb 12, 2025ORKA
Oruka Therapeutics, Inc.
Purchase(P)Indirect9K shares at avg. $11.86$106K - Feb 12, 2025KALV
KalVista Pharmaceuticals, Inc.
Purchase(P)Indirect100K shares at avg. $9.23$923K - Feb 11, 2025ORKA
Oruka Therapeutics, Inc.
Purchase(P)Indirect9.6K shares at avg. $10.95$105K - Feb 11, 2025KALV
KalVista Pharmaceuticals, Inc.
Purchase(P)Indirect26.7K shares at avg. $9.18$245K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 30, 2026 |  LYCA Lycia Therapeutics, Inc. | Purchase(P) | 8,804 | $26.27 | $231,281 | Indirect |
| Oct 30, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 200 | $26.86 | $5,372 | Indirect |
| Oct 29, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 1,000 | $26.33 | $26,330 | Indirect |
| Oct 28, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 4,430 | $25.97 | $115,047 | Indirect |
| Oct 28, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 10,570 | $25.23 | $266,681 | Indirect |
| Oct 27, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 8,729 | $25.84 | $225,557 | Indirect |
| Oct 27, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 31,067 | $26.84 | $833,838 | Indirect |
| Oct 26, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 8,261 | $26.97 | $222,799 | Indirect |
| Oct 26, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 1,944,444 | $18.00 | $34,999,992 | Indirect |
| Oct 26, 2026 | LYCA Lycia Therapeutics, Inc. | Conversion(C) | 4,779,793 | - | $0 | Indirect |
| Oct 23, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 24,560 | $25.68 | $630,701 | Indirect |
| Oct 23, 2026 | LYCA Lycia Therapeutics, Inc. | Purchase(P) | 28,379 | $26.11 | $740,976 | Indirect |
| Mar 26, 2026 |  KALV KalVista Pharmaceuticals, Inc. | Sale(S) | 15,417 | $18.82 | $290,148 | Indirect |
| Mar 26, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale(S) | 3,183 | $19.12 | $60,859 | Indirect |
| Mar 26, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale(S) | 21,386 | $17.76 | $379,815 | Indirect |
| Mar 25, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale(S) | 174,485 | $16.95 | $2,957,521 | Indirect |
| Mar 25, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale(S) | 160 | $17.53 | $2,805 | Indirect |
| Apr 9, 2025 | KALV KalVista Pharmaceuticals, Inc. | Purchase(P) | 25,000 | $9.42 | $235,500 | Indirect |
| Feb 14, 2025 |  ORKA Oruka Therapeutics, Inc. | Purchase(P) | 88,794 | $11.44 | $1,015,803 | Indirect |
| Feb 13, 2025 | ORKA Oruka Therapeutics, Inc. | Purchase(P) | 14,950 | $11.63 | $173,869 | Indirect |
| Feb 13, 2025 | KALV KalVista Pharmaceuticals, Inc. | Purchase(P) | 61,700 | $9.33 | $575,661 | Indirect |
| Feb 12, 2025 | ORKA Oruka Therapeutics, Inc. | Purchase(P) | 8,971 | $11.86 | $106,396 | Indirect |
| Feb 12, 2025 | KALV KalVista Pharmaceuticals, Inc. | Purchase(P) | 100,000 | $9.23 | $923,000 | Indirect |
| Feb 11, 2025 | ORKA Oruka Therapeutics, Inc. | Purchase(P) | 9,593 | $10.95 | $105,043 | Indirect |
| Feb 11, 2025 | KALV KalVista Pharmaceuticals, Inc. | Purchase(P) | 26,703 | $9.18 | $245,134 | Indirect |
1-25 of 31 transactions
About Venrock Healthcare Capital Partners III, L.P.
Venrock Healthcare Capital Partners III, L.P. (SEC CIK 0001738048) files insider reports with the SEC as 10% Owner of Lycia Therapeutics, Inc. (LYCA), 10% Owner of KalVista Pharmaceuticals, Inc. (KALV) and 10% Owner of Oruka Therapeutics, Inc. (ORKA).
Signal8 holds 11 ownership filings by Venrock Healthcare Capital Partners III, L.P. (3 Form 3, 8 Form 4), filed between Feb 3, 2025 and Oct 30, 2026. Those filings report 31 transactions, from Jan 30, 2025 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Venrock Healthcare Capital Partners III, L.P.'s filings is in NEW YORK, NY.
Recent filings by Venrock Healthcare Capital Partners III, L.P.
- Oct 30, 2026: Open-market purchases of LYCA shares (2 lines, Form 4, code P).
- Oct 29, 2026: Open-market purchase of LYCA shares (Form 4, code P).
- Oct 28, 2026: Open-market purchases of LYCA shares (2 lines, Form 4, code P).
- Oct 27, 2026: Open-market purchases of LYCA shares (2 lines, Form 4, code P).
- Oct 26, 2026: Open-market purchases of LYCA shares (2 lines, Form 4, code P).
Other insiders filing for Lycia Therapeutics, Inc. (LYCA)
- Versant Ventures VII GP, L.P., 10% Owner
- Fischer Laurent, Director
- Henderson Jane, Director
- RIEFLIN WILLIAM JL, Director
- Touami Sofia, Chief Business Officer
- Staben Steven, Chief Scientific Officer